Time to include Human TSP2 in your next NASH study?
Posted: September 14, 2022
It’s Not Just Support. It’s Solutions.
Time to include Thrombospondin-2 in your next NASH study…
- Thrombospondin-2 has been identified by transcriptomics as an emerging NASH biomarker.
- Protein analysis shows that it has promise for use in studying NAFLD, NASH, metabolic disease, and diabetes.
- This Human TSP2 ELISA kit, from ImmunoDiagnostics, is proven reliable for clinical research samples related to NASH and diabetes.
Connect with a DiaPharma scientist to learn more about ImmunoDiagnostics Human Thrombospondin-2 (TSP2) ELISA Kit.
Visit DiaPharma at AASLD The Liver Meeting® to discuss our entire offering for blood based liver biomarkers to study Non-alcoholic Steatohepatitis (NASH), Alcoholic Hepatitis (AH) and Drug Induced Liver Injury (DILI).
About ImmunoDiagnostics: ImmunoDiagnostics Limited (IMD) is a spin-off biotech company from Immunoassay Services (AIS) from the University of Hong Kong (HKU), and has R&D activities in both Toronto and Hong Kong. IMD’s Mission is to be the worldwide pioneer in the production and manufacture of research products regarding immuno-metabolism. READ MORE
Further Reading:
- Wu X, Cheung CKY, Ye D, et al. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease. J Clin Endocrinol Metab. 2022;107(8):e3230-e3240. doi:10.1210/clinem/dgac292
- Kozumi K, Kodama T, Murai H, et al. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. 2021;74(5):2452-2466. doi:10.1002/hep.31995
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00967Rev01